ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02465567
Recruitment Status : Active, not recruiting
First Posted : June 8, 2015
Last Update Posted : August 15, 2018
Sponsor:
Information provided by (Responsible Party):
Pearl Therapeutics, Inc.

Brief Summary:
This is a randomized, double-blind, multi-center, parallel-group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations subjects with moderate to very severe COPD.

Condition or disease Intervention/treatment Phase
COPD Drug: BGF MDI 320/14.4/9.6 μg Drug: GFF MDI 14.4/9.6 μg Drug: BGF MDI 160/14.4/9.6 μg Drug: BFF MDI 320/9.6 μg Phase 3

Detailed Description:
A randomized, double-blind, multi-center, parallel-group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations over a 52-week treatment period in subjects with moderate to very severe COPD.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8564 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Multi-Center, Parallel-Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD (Ethos)
Actual Study Start Date : June 30, 2015
Estimated Primary Completion Date : June 19, 2019
Estimated Study Completion Date : June 19, 2019

Arm Intervention/treatment
Experimental: BGF (PT010) MDI 320/14.4/9.6 μg
BGF MDI 320/14.4/9.6 μg, Budesonide, Glycopyrronium, Formoterol Fumarate Aerosol (PT010, BGF metered dose inhaler [MDI])
Drug: BGF MDI 320/14.4/9.6 μg
Budensonide, Glycopyrronium, and Formoterol Fumarate
Other Name: BGF

Experimental: BGF (PT010) MDI 160/14.4/9.6 μg
BGF MDI 160/14.4/9.6 μg, Budesonide, Glycopyrronium, Formoterol Fumarate Aerosol (PT010, BGF metered dose inhaler [MDI])
Drug: BGF MDI 160/14.4/9.6 μg
Budensonide, Glycopyrronium, and Formoterol Fumarate
Other Name: BGF

Experimental: BFF (PT009) MDI 320/9.6 μg
BFF MDI 320/9.6 μg Budesonide, Formoterol Fumarate Aerosol Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)
Drug: BFF MDI 320/9.6 μg
Budensonide, and Formoterol Fumarate
Other Name: BFF

Experimental: GFF (PT003) MDI 14.4/9.6 μg
GFF MDI 14.4/9.6 μg Glycopyrronium, Formoterol Fumarate Aerosol Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)
Drug: GFF MDI 14.4/9.6 μg
Glycopyrronium, and Formoterol Fumarate
Other Name: GFF




Primary Outcome Measures :
  1. Rate of moderate or severe exacerbations [ Time Frame: (52-week treatment period) ]
    Rate of moderate or severe exacerbations


Secondary Outcome Measures :
  1. Time to first moderate or severe COPD exacerbation [ Time Frame: 52 Weeks ]
    Time to first moderate or severe COPD exacerbation

  2. Change from baseline in average daily rescue Ventolin HFA use over 24 weeks [ Time Frame: 24 Weeks ]
    Change from baseline in average daily rescue Ventolin HFA use over 24 weeks

  3. Percentage of subjects achieving a minimal clinically important difference [ Time Frame: 24 Weeks ]
    Percentage of subjects achieving a minimal clinically important difference of 4 units or more in SGRQ total score at Week 24

  4. Time to death (all cause) [ Time Frame: 52 Weeks ]
    Time to death (all cause)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Non-child bearing potential (ie, physiologically incapable of becoming pregnant, including any female who is 2 years post-menopausal); or Child bearing potential, has a negative serum pregnancy test at Visit 1, and agrees to acceptable contraceptive methods used consistently and correctly for the duration of the study.
  • Subjects with an established clinical history of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS),
  • Current or former smokers with a history of at least 10 pack-years of cigarette smoking.
  • Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) ratio must be <0.70 and FEV1 must be <65% predicted normal value calculated using NHANES III reference equations (or reference norms applicable to other regions).
  • Subjects with history of exacerbations.

Please refer to the study protocol for the complete inclusion criteria list.

Exclusion Criteria

  • Significant diseases or conditions other than COPD, which, in the opinion of the Investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study.
  • Women who are pregnant or lactating, or are planning to become pregnant during the course of the study, or women of childbearing potential who are not using an acceptable method of contraception.
  • Subjects, who in the opinion of the Investigator, have a current diagnosis of asthma.
  • Subjects who have been hospitalized due to poorly controlled COPD within 3 months prior to Visit 1 (Screening)
  • Subjects who have poorly controlled COPD, defined as acute worsening of COPD that requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to Visit 1 (Screening)
  • Immune suppression or severe neurological disorders affecting control of the upper airway or other risk factors that in the opinion of the Investigator would put the subject at substantial risk of pneumonia.
  • Subjects with a diagnosis of narrow angle glaucoma, who, in the opinion of the Investigator, have not been adequately treated.
  • Subjects who have a history of hypersensitivity to β2-agonists, budesonide or any other corticosteroid components, glycopyrronium or other muscarinic anticholinergics, or any other component of the IMPs.

Please refer to the study protocol for the complete inclusion criteria list.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02465567


  Show 712 Study Locations
Sponsors and Collaborators
Pearl Therapeutics, Inc.
Investigators
Study Director: Paul M Dorinsky, MD Pearl Therapeutics

Responsible Party: Pearl Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT02465567     History of Changes
Other Study ID Numbers: PT010005
First Posted: June 8, 2015    Key Record Dates
Last Update Posted: August 15, 2018
Last Verified: August 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Formoterol Fumarate
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action